ArticleFrontiers in oncology2022
Axillary lymph node dissection combined with radiotherapy for trichilemmal carcinoma with giant lymph node metastasis: A case report.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Review
- The clinicopathological features, treatment patterns, and prognosis of trichilemmal carcinoma: a retrospective case-series study.American journal of cancer research · 2025Article
- Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review.Immunotherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trichilemmal carcinoma (TC) is a rare malignancy with a poor outcome if local recurrence and distant metastasis occur. There is no treatment strategy for such a disease. Case presentation: We reported a complicated case of TC in the right lower abdomen with ipsilateral axillary and inguinal lymph node metastases. After surgery and radiotherapy, there has been no recurrence or metastasis in the follow-up to date. Conclusion: We believe that even though considered a tumor of low malignant potential, TC still has the risk of recurrence and metastasis, and the lymph node status should be identified if a high suspicion or diagnosis is made. Regional lymph node dissection followed by local radiotherapy is recommended as the optimal treatment strategy for patients with lymph node metastases of TC. Screening for metastasis and close follow-up are indispensable for improving prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.